Boehringer hits China’s Qilu with cancer drug patent suit
04-02-2021
Boehringer Ingelheim loses parasite control patent appeal
21-09-2020
English court gives Mylan green-light to sell generic insomnia drug
04-06-2020
ricochet64 / Shutterstock.com
The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Mylan, Federal Circuit, Boehringer Ingelheim, type 2 diabetes, DPP-IV inhibitor, US District Court for the District of New Jersey, patent invalidation
